Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bf9a8eaf4cfdf1a95f47fba0023a83ec4> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bf9a8eaf4cfdf1a95f47fba0023a83ec4 NCIT_P378 "NCI" @default.
- Bf9a8eaf4cfdf1a95f47fba0023a83ec4 type Axiom @default.
- Bf9a8eaf4cfdf1a95f47fba0023a83ec4 annotatedProperty IAO_0000115 @default.
- Bf9a8eaf4cfdf1a95f47fba0023a83ec4 annotatedSource NCIT_C172825 @default.
- Bf9a8eaf4cfdf1a95f47fba0023a83ec4 annotatedTarget "A low-dose formulation of aldesleukin, a recombinant analog of the human endogenous cytokine interleukin-2 (IL-2), with potential immunoregulatory activity. Upon administration of low-dose aldesleukin ILT-101, this agent binds to and activates the IL-2 receptor (IL2R), thereby activating IL2R-mediated signaling. This enhances the expansion and stimulation of regulatory T cells (Tregs). This prevents excessive inflammation and autoimmunity. It also blocks the differentiation of CD4 naïve T cells into follicular helper or proinflammatory helper 17 (Th17) T cells. Tregs, a subpopulation of CD4+ T cells, plays a key role in the control of immune responses and T-cell immune tolerance. Activation of IL2R with low dose IL-2 preferentially induces Tregs development and activation while activation of IL2R with high dose IL-2 induces the activation of T effector (Teff) cells." @default.